Global Longlife Hospital And Research Ltd vs Sharma East India Hosp And Medical Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.82 as of 30 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 25.7 on March 2023 to 0 on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Sharma East India Hosp and Medical Research Ltd changed from 24.9 on March 2025 to 34.6 on March 2026 . This represents a CAGR of 17.88% over 2 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 47.02 crore on March 2023 to ₹ 14.34 crore on March 2026 . This represents a CAGR of -25.69% over 4 yearsThe Market Cap of Sharma East India Hosp and Medical Research Ltd changed from ₹ 24.42 crore on March 2025 to ₹ 33.94 crore on March 2026 . This represents a CAGR of 17.89% over 2 years The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 10.8 crore as compare to the Mar '26 revenue of ₹ 7.49 crore. This represent the growth of 44.19% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sharma East India Hosp and Medical Research Ltd for the Jun '26 is ₹ 0.9 crore as compare to the Mar '26 ebitda of ₹ 1.03 crore. This represent the decline of -12.62% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Sharma East India Hosp and Medical Research Ltd changed from ₹ 0.25 crore to ₹ 0.26 crore over 9 quarters. This represents a CAGR of 1.76% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Sharma East India Hosp and Medical Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution that offer to every human being, high quality healthcare at affordable prices in Ahmedabad. Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About Sharma East India Hosp and Medical Research Ltd

Sharma East India Hospitals & Medical Research Limited was incorporated on November 16, 1989.
The Company is engaged in providing medical and healthcare services and real estate services and is presently running a multi-specialty hospital in the name of 'Jaipur Hospital' at Lal Kothi, at Rajasthan since 1989. As far as the achievements of the Company are concerned, the first assessment of the Company was conducted by National Accreditation Board for Hospitals and Health Care Providers (NABH), NABH accreditation system is one of the methods for commitment to quality enhancement throughout whole of the health care system in India.
It involves all professional and service groups to ensure that high quality in health care is achieved, while minimizing the inherent risks associated with modern health care delivery.

FAQs for the comparison of Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or Sharma East India Hosp and Medical Research Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of Sharma East India Hosp and Medical Research Ltd is 26 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd?

As of November 1, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.82. On the other hand, Sharma East India Hosp and Medical Research Ltd stock price is INR ₹80.0.

How do dividend payouts of Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and Sharma East India Hosp and Medical Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.